Author Interviews, COVID -19 Coronavirus, Lancet, Rheumatology / 08.05.2020
Repurposed Rheumatology Drug May Reduce Inflammation in COVID-19 Infection
MedicalResearch.com Interview with:
Dr. Giulio Cavalli MD PhD &
Prof. Lorenzo Dagna MD FACP
Ospedale San Raffaele and
Vita-Salute San Raffaele University
Milan, Italy
MedicalResearch.com: What is the background for this study?
Response: Upon encountering pathogens, our immune system produces pro-inflammatory mediators, called cytokines. Cytokines activate cells from the immune system. In most people, production of cytokines is an appropriate and protective response to infection. However, some individuals develop excessive and detrimental inflammatory responses, which are even more harmful than the pathogen itself to the host organism.
We hypothesized that some patients with COVID-19 might develop excessive and detrimental inflammation, and that treatment with anti-inflammatory agents might be beneficial in this population.
Anakinra is an inhibitor of the pro-inflammatory molecule interleukin 1 (IL-1). It was originally marketed for the treatment of rheumatoid arthritis, but is now mostly used to treat a variety of pediatric inflammatory diseases. (more…)